None of the surgeons in this segment had used the device. Kind of hard to give an opinion based on conjecture isn't it ? One of the surgeons did not even do reconstruction. Getting surgeons to use the device has not been the issue as I understand it. Getting them to use it on a wide variety of patients and adopt it as their product of choice has. Things like using the device with radiotherapy and some of the other things the company mentioned in their call all seem to be credible areas of objections. Quarterly performance will tell now right ?
Ann: Results of 2018 Annual Meeting of Stockholders, page-70
-
- There are more pages in this discussion • 22 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AXP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $5.824M | |||
| Open | High | Low | Value | Volume |
| 0.2¢ | 0.2¢ | 0.1¢ | $3.052K | 1.651M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 32 | 43009120 | 0.1¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.2¢ | 90779583 | 59 |
View Market Depth
| Last trade - 16.10pm 29/11/2024 (20 minute delay) ? |
| AXP (ASX) Chart |
